# Comparing the outcomes

> Four outcomes | Peptide Research Outlet — Compare NAD+, retatrutide, BPC-157 and thymosin alpha-1 at Peptide Research Outlet by the actual outcome: metabolism, weight, blood supply or survival.

The measurement that convinces me changes with the job. Weight, circulation, muscle glucose handling and survival deserve their own columns.

## Results beside their intended jobs

The word activity can hide an enormous difference in what actually happened. A receptor can respond in a dish, blood flow can recover in a rat, and a person can survive an illness. Each observation matters at its own scale.

Ranking these compounds obscures the jobs that interest me. NAD+ is chemically a coenzyme; the other subjects are peptides. The useful comparison begins with the outcome, then checks the setting in which it was measured.

| Subject | Work being examined | Finding in the record | Remaining question |
|---|---|---|---|
| NAD+ precursors | Cellular supply and metabolic function | [NMN improved muscle insulin sensitivity in postmenopausal women with prediabetes](https://pubmed.ncbi.nlm.nih.gov/33888596/); HbA1c and body composition stayed unchanged | Does the measured change produce lasting health benefit? |
| Retatrutide | Appetite and metabolic signalling | [Phase 2 human trials found weight loss](https://pubmed.ncbi.nlm.nih.gov/37366315/); liver-fat and diabetes studies found changes in their own populations | How durable are the benefits, and what are the longer-term risks? |
| BPC-157 | Blood supply and repair | [Vessel growth and blood-flow recovery improved in animal and cell models](https://pubmed.ncbi.nlm.nih.gov/27847966/) | Do injured people recover better? |
| Thymosin alpha-1 | Immune response during severe illness | [The phase 3 sepsis trial found no significant survival benefit](https://pubmed.ncbi.nlm.nih.gov/39814420/) | Which other clinical settings, if any, have dependable benefits? |

## Where I put the emphasis

For NAD+ precursors, the [review of human ageing research](https://pubmed.ncbi.nlm.nih.gov/41083806/) makes tissue-specific evidence a pressing gap. A higher blood level leaves much of the body unexplained. For BPC-157, the [human evidence review](https://pubmed.ncbi.nlm.nih.gov/40789979/) makes a different shortage plain: rigorous large-scale human trials are lacking.

Retatrutide already has measured human weight outcomes in this record. The [heart-rate and gastrointestinal findings in the obesity trial](https://pubmed.ncbi.nlm.nih.gov/37366315/) belong in the same appraisal as the weight loss. Thymosin alpha-1 presents the reverse temptation: discarding the disappointing survival result because a cellular explanation remains attractive.

I give a clear disappointment more weight than a mechanism pressed into the wrong job. That still leaves plenty to investigate. The linked subject pages pursue [NAD+](/nad), [retatrutide](/retatrutide), [BPC-157](/bpc-157) and [thymosin alpha-1](/thymosin-alpha-1) as separate stories.

---

An independent evidence-stage digest that tracks peptide claims from first report to peer review, never a storefront or a substitute for clinical judgment.